Cargando…
Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial
BACKGROUND: The additive benefit of inhaled corticosteroid when used with systemic corticosteroid in acute asthma is still unclear. The objective of this study was to assess the effect of high and repeated doses of inhaled budesonide when combined with the standard treatment of adult acute asthma. M...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308286/ https://www.ncbi.nlm.nih.gov/pubmed/35870902 http://dx.doi.org/10.1186/s12873-022-00691-9 |
_version_ | 1784752954065027072 |
---|---|
author | Marghli, Soudani Bouhamed, Chafiaa Sghaier, Amira Chebbi, Nabil Dlala, Insaf Bettout, Samia Belkacem, Achref Kbaier, Sarra Jerbi, Nahla Bellou, Abdelouahab |
author_facet | Marghli, Soudani Bouhamed, Chafiaa Sghaier, Amira Chebbi, Nabil Dlala, Insaf Bettout, Samia Belkacem, Achref Kbaier, Sarra Jerbi, Nahla Bellou, Abdelouahab |
author_sort | Marghli, Soudani |
collection | PubMed |
description | BACKGROUND: The additive benefit of inhaled corticosteroid when used with systemic corticosteroid in acute asthma is still unclear. The objective of this study was to assess the effect of high and repeated doses of inhaled budesonide when combined with the standard treatment of adult acute asthma. METHODS: It was a prospective double-blind randomized controlled study performed in the emergency department (ED) from May 1, 2010 to February 28, 2011 (ClinicalTrials.gov, NCT04016220). Fifty patients were included and were randomized to receive intravenous hydrocortisone hemisuccinate in association with nebulized budesonide (n = 23, budesonide group) or normal saline (n = 27, control group). Nebulization of budesonide or saline was done in combination with 5 mg of terbutaline every 20 min the first hour, then at 2 h (H2), and 3 h (H3). All patients received standard treatment. Efficacy and safety of inhaled budesonide were evaluated every 30 min for 180 min. RESULTS: A significant increase in peak expiratory flow (PEF) was observed in both treatment groups at evaluation times. The increase in PEF persisted significantly compared to the previous measurement in both groups. There was no significant difference in the PEF between the two groups at evaluation times. There was no significant difference between the two groups in the evolution in the respiratory rate and heart rate. There was also no statistically significant difference between the two groups in the rate of hospitalization, the discharge criteria before the end of the protocol. CONCLUSIONS: Considering its limited power, our study suggests that the association of nebulized budesonide with hydrocortisone hemisuccinate has no additional effect over the use of hydrocortisone alone in adults’ acute asthma managed in the ED. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12873-022-00691-9. |
format | Online Article Text |
id | pubmed-9308286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93082862022-07-24 Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial Marghli, Soudani Bouhamed, Chafiaa Sghaier, Amira Chebbi, Nabil Dlala, Insaf Bettout, Samia Belkacem, Achref Kbaier, Sarra Jerbi, Nahla Bellou, Abdelouahab BMC Emerg Med Research BACKGROUND: The additive benefit of inhaled corticosteroid when used with systemic corticosteroid in acute asthma is still unclear. The objective of this study was to assess the effect of high and repeated doses of inhaled budesonide when combined with the standard treatment of adult acute asthma. METHODS: It was a prospective double-blind randomized controlled study performed in the emergency department (ED) from May 1, 2010 to February 28, 2011 (ClinicalTrials.gov, NCT04016220). Fifty patients were included and were randomized to receive intravenous hydrocortisone hemisuccinate in association with nebulized budesonide (n = 23, budesonide group) or normal saline (n = 27, control group). Nebulization of budesonide or saline was done in combination with 5 mg of terbutaline every 20 min the first hour, then at 2 h (H2), and 3 h (H3). All patients received standard treatment. Efficacy and safety of inhaled budesonide were evaluated every 30 min for 180 min. RESULTS: A significant increase in peak expiratory flow (PEF) was observed in both treatment groups at evaluation times. The increase in PEF persisted significantly compared to the previous measurement in both groups. There was no significant difference in the PEF between the two groups at evaluation times. There was no significant difference between the two groups in the evolution in the respiratory rate and heart rate. There was also no statistically significant difference between the two groups in the rate of hospitalization, the discharge criteria before the end of the protocol. CONCLUSIONS: Considering its limited power, our study suggests that the association of nebulized budesonide with hydrocortisone hemisuccinate has no additional effect over the use of hydrocortisone alone in adults’ acute asthma managed in the ED. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12873-022-00691-9. BioMed Central 2022-07-23 /pmc/articles/PMC9308286/ /pubmed/35870902 http://dx.doi.org/10.1186/s12873-022-00691-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Marghli, Soudani Bouhamed, Chafiaa Sghaier, Amira Chebbi, Nabil Dlala, Insaf Bettout, Samia Belkacem, Achref Kbaier, Sarra Jerbi, Nahla Bellou, Abdelouahab Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial |
title | Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial |
title_full | Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial |
title_fullStr | Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial |
title_full_unstemmed | Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial |
title_short | Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial |
title_sort | nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308286/ https://www.ncbi.nlm.nih.gov/pubmed/35870902 http://dx.doi.org/10.1186/s12873-022-00691-9 |
work_keys_str_mv | AT marghlisoudani nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT bouhamedchafiaa nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT sghaieramira nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT chebbinabil nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT dlalainsaf nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT bettoutsamia nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT belkacemachref nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT kbaiersarra nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT jerbinahla nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial AT bellouabdelouahab nebulizedbudesonidecombinedwithsystemiccorticosteroidvssystemiccorticosteroidaloneinacutesevereasthmamanagedintheemergencydepartmentarandomizedcontrolledtrial |